Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01586273
Other study ID # 906273
Secondary ID
Status Terminated
Phase N/A
First received April 24, 2012
Last updated April 3, 2017
Start date September 2012
Est. completion date November 2016

Study information

Verified date April 2017
Source Philips Healthcare
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness of the Philips Sonalleve Magnetic Resonance Imaging-guided High Intensity Focused Ultrasound (MR-HIFU) device for treating painful bone metastases.


Description:

Magnetic Resonance Imaging-guided High Intensity Focused Ultrasound (MR-HIFU) is a non-invasive outpatient modality. In MR-HIFU, a specially designed ultrasound transducer is used to focus a beam of ultrasound energy into a small volume at a specific target site in the body. The focused beam is intended to produce therapeutic hyperthermia in the target field while only harmlessly warming the immediately surrounding tissue. Magnetic Resonance Imaging is used during the ultrasound treatment, both to focus the ultrasound beam on the target field and to perform real-time thermal mapping at and around the target.

The Philips Sonalleve MR-HIFU system is expected to be efficacious in reducing pain scores in patients with painful bone metastases and in reducing their pain medication usage.


Recruitment information / eligibility

Status Terminated
Enrollment 20
Est. completion date November 2016
Est. primary completion date September 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Men and women with age = 18 years

- Patient capable of giving informed consent and able to attend study visits

- Weight < 140kg

- Radiologic evidence of bone metastases from any solid tumor

- Diagnosis of dominant painful bone metastasis (Numerical Representative Scale (NRS) pain score =4), either refractory to standard of care (including radiotherapy and optimal pain medication) or standard of care is contra-indicated or refused by patient.

- Patient has been on stable pain medication for at least 1 week prior to HIFU treatment date

- Pain is localized to the targeted area, or is likely to be referred pain arising from the targeted area

- Patient has 1-3 painful lesions, and only the most painful lesion will be treated

- Intended Target Volume accessible for MR-HIFU procedure

- Target lesion maximum dimension = 8cm

- Intended target volume visible by non-contrast MRI

- Distance between target and skin = 1cm

- Patient is able to communicate sensation during MR-HIFU treatment

- MR-HIFU treatment date = 4 weeks from last local treatment of the target lesion

Exclusion Criteria:

- Planned treatment lesion is a primary bone tumor or due to lymphoma, multiple myeloma, or leukemia.

- Communication barrier present

- Patient enrolled in another clinical study related to bone metastases treatment or pain relief treatment

- Unable to tolerate required stationary position during treatment

- Need for surgical stabilization in case of (impending) fracture (lytic lesion in weight-bearing bone larger than 50% of bone diameter)

- Pregnant woman

- Pain related to target lesion is predominantly due to fracture or impending fracture

- Pain related to target lesion is due to involvement of a neighboring major nerve by the metastatic tumor (cord or nerve compression)

- Target < 3cm from bladder / bowel / nerve along the beam path and < 1cm in the plane orthogonal to the beam

- Target in contact with hollow viscera

- Target located in skull, joints, ribs (when HIFU beam overlapping with lung), spine (excluding sacrum which is allowed) or sternum

- Scar along proposed HIFU beam path

- Internal or external fixation device along the proposed HIFU beam path or at the target

- MRI contraindicated (e.g. paramagnetic implants, pacemaker, claustrophobia)

- MRI contrast agent contraindicated (e.g. previous anaphylaxis or Glomerular Filtration Rate (GFR) < 30 ml/min/1.73m2)

- Sedation contraindicated

- Previous surgery or minimally invasive treatment at targeted site

- Clinically relevant medical history or abnormal physical findings that could interfere with the safety of the participant as judged by the treating physician or investigator

Study Design


Intervention

Device:
MR-HIFU treatment for pain palliation of bone metastases
A treatment session with the Philips Sonalleve MR-HIFU device for bone pain palliation with high-intensity focused ultrasound.

Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul
Netherlands University Medical Center Utrecht Utrecht
United Kingdom Royal Marsden Hospital / Institute of Cancer Research Sutton Surrey

Sponsors (1)

Lead Sponsor Collaborator
Philips Healthcare

Countries where clinical trial is conducted

Korea, Republic of,  Netherlands,  United Kingdom, 

References & Publications (7)

Catane R, Beck A, Inbar Y, Rabin T, Shabshin N, Hengst S, Pfeffer RM, Hanannel A, Dogadkin O, Liberman B, Kopelman D. MR-guided focused ultrasound surgery (MRgFUS) for the palliation of pain in patients with bone metastases--preliminary clinical experience. Ann Oncol. 2007 Jan;18(1):163-7. Epub 2006 Oct 9. — View Citation

Chow E, Hird A, Velikova G, Johnson C, Dewolf L, Bezjak A, Wu J, Shafiq J, Sezer O, Kardamakis D, Linden Yv, Ma B, Castro M, Arnalot PF, Ahmedzai S, Clemons M, Hoskin P, Yee A, Brundage M, Bottomley A; EORTC Quality of Life Group.; Collaboration for Cancer Outcomes Research and Evaluation.. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22. Eur J Cancer. 2009 May;45(7):1146-52. doi: 10.1016/j.ejca.2008.11.013. Epub 2008 Dec 25. — View Citation

Chow E, Hoskin P, Mitera G, Zeng L, Lutz S, Roos D, Hahn C, van der Linden Y, Hartsell W, Kumar E; International Bone Metastases Consensus Working Party.. Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1730-7. doi: 10.1016/j.ijrobp.2011.02.008. Epub 2011 Apr 12. — View Citation

Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994 Mar;23(2):129-38. Review. — View Citation

Gianfelice D, Gupta C, Kucharczyk W, Bret P, Havill D, Clemons M. Palliative treatment of painful bone metastases with MR imaging--guided focused ultrasound. Radiology. 2008 Oct;249(1):355-63. doi: 10.1148/radiol.2491071523. Epub 2008 Aug 11. — View Citation

Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley A, Fayers PM, de Graeff A, Hammerlid E, Kaasa S, Sprangers MA, Bjorner JB; EORTC Quality of Life Group.. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer. 2006 Jan;42(1):55-64. Epub 2005 Sep 12. — View Citation

Liberman B, Gianfelice D, Inbar Y, Beck A, Rabin T, Shabshin N, Chander G, Hengst S, Pfeffer R, Chechick A, Hanannel A, Dogadkin O, Catane R. Pain palliation in patients with bone metastases using MR-guided focused ultrasound surgery: a multicenter study. Ann Surg Oncol. 2009 Jan;16(1):140-6. doi: 10.1245/s10434-008-0011-2. Epub 2008 Nov 11. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Pain response to therapy Pain is measured using the Brief Pain Inventory (BPI) questionnaire. Patients are categorized into:
Complete response (CR): Pain score 0 without analgesic increase
Partial response (PR): Pain reduction of 2 or more without analgesic increase; or analgesic reduction of 25% without pain increase
Pain Progression (PP): Pain increase of 2 or more with stable analgesic use; or increase of 25% or more in analgesic use, with pain score stable or 1 point above baseline
No response corresponds to all other cases
Patients with PR or CR at 30 days are considered responders to therapy.
30 days after treatment
Secondary Total number of Adverse Events Total number of complications and adverse events, including the number of unintended lesions that occur as a result of treatment with MR-HIFU. within the first 90 days within treatment
Secondary Quality of Life (as measured by questionnaire) Quality of Life will be measured at the given time points using a dedicated questionnaire for patients in palliative care: the European Organisation on Research and Treatment of Cancer (EORTC) C15-PAL questionnaire. at day 0 before treatment, and at 7, 14, 30, 60 and 90 days after treatment
Secondary Subgroup analysis: pain response in radiation naïve patients Assessment of positive response on pain (as determined by the Primary Outcome Measure) will be documented separately for radiation naïve patients and radiation failure patients, and a comparison between the two sub-groups will be performed. 30 days after treatment
Secondary Temporal evolution of pain response during the first 30 days after treatment Patients are given a diary to complete during the first 30 days after treatment, which documents their daily pain level on a 0-10 scale and their pain medication usage. during the first 30 days after treatment
See also
  Status Clinical Trial Phase
Completed NCT01833806 - A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain N/A
Completed NCT02609828 - Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy Phase 3
Completed NCT04592887 - Feasibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases N/A
Recruiting NCT02231476 - Efficacy of Radiotherapy in Combination With Zoledronic Acid on Pain Relief in Bone Metastasis Patients Phase 2
Recruiting NCT02426697 - Pain Management With Pecfent in the Prevention of Pain Induced by Position in Radiotherapy Phase 3
Completed NCT00334139 - Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer Phase 4
Completed NCT01784393 - Chemoradiation for Bone Metastasis Phase 2
Terminated NCT02999152 - Validation of Radio-induced Damage Biomarkers N/A
Not yet recruiting NCT02480634 - Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer Phase 4
Completed NCT02784652 - Efficacy of Radiotherapy in Combination With Zoledronic Acid in Bone Metastasis Patients With Gastrointestinal Tumors Phase 2
Completed NCT02774213 - A Study to Collect Data About Analgesia in Patients With Bone Metastasis
Completed NCT02673060 - A Trial of MBC-11 in Patients With CIBD Phase 1
Completed NCT02876731 - Comparison of NaF PET-CT and Diffusion MRI in the Diagnosis of Bone Metastases (IMMETAOS) N/A
Recruiting NCT02705157 - The OPTIMAL Study - A Prospective Cohort of Patients With Bone Metastases of the Long Bones N/A
Completed NCT01309048 - Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases Phase 1/Phase 2
Completed NCT01062503 - Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC N/A
Completed NCT00610272 - Optimization of Radiotherapy in Treatment of Painful Bone Metastasis Phase 3
Completed NCT01998607 - Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw N/A
Recruiting NCT02876991 - Evaluation of Sodium Fluoride PET in the Identification of Bone Metastases in Patients Having Undergone a Choline PET for Occult Recurrence of Prostatic Adenocarcinoma N/A
Completed NCT02293642 - Bone Pain Score Validation Initiative